Tajikistan Medical Device Documentation: Tajik and Russian Language Requirements

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The linguistic landscape of Tajikistan is Tajik as the state language and Russian as the language of interethnic communication, yet Law No. 1893 does not prescribe, at the statutory level, which language must be used for registration materials, labels or instructions for use. The GRZAN guiding principle is that, for anything the law does not specify, one must turn to the procedural documents of the Ministry of Health. At the same time, three indirect bases can be derived from the structure of the legal text: Article 1(21), under which the instructions for use are an approved document; Article 43(2), under which labelling and packaging requirements are developed by the Ministry of Health; and Article 44(5), under which registration and withdrawal information is published by the supervisory authority in the relevant publications, the language of publication implying the official languages of the Tajik side.

2. Legal basis

ItemContent
Legal basisLaw of the Republic of Tajikistan on Medicines, Medical Products and Pharmaceutical Activities, No. 1893 of July 19, 2022 (re-enacted by Law No. 2181 of May 14, 2025)
Instructions for useArticle 1(21): instructions for use of medicines, medical products and quasi-medicinal products mean a document approved under the procedure determined by the Ministry of Health, containing information on the methods and manner of use
Labelling competenceArticle 43(2): the development and approval of labelling and packaging requirements is the responsibility of the Ministry of Health
Information disclosureArticle 44(5): information on state registration decisions, withdrawal of state registration and non-conformity with quality standards is published by the supervisory authority in the relevant publications
Advertising textsArticle 45(6): advertising texts must be coordinated with the supervisory authority and must conform to the instructions for use
Aid standardsArticle 24(1): medicines and medical products supplied for humanitarian purposes must meet the quality standards of the Republic of Tajikistan and international standards
Foreign standardsArticle 8(17): the Ministry of Health may, where necessary, recognize the pharmacopoeias and quality standards of other countries for medicines and medical products
Procedural competenceArticle 17(12): the procedures for registration, re-registration of medical products and quasi-medicinal products, and amendments are developed and approved by the Ministry of Health

3. Expert insights

Insight 1: Law No. 1893 contains no language provision anywhere in its text, which distinguishes it from most CIS countries. The device regulations of countries such as Kyrgyzstan and Kazakhstan typically contain explicit label language clauses, such as bilingual Russian plus the national language. Law No. 1893 of Tajikistan contains no such clause. The GRZAN judgment is that language requirements have been delegated to Ministry of Health procedural documents and labelling specifications. The direct consequence is that companies cannot derive language requirements from the legal text and must request the currently valid specification documents.

Insight 2: Article 1(21) and Article 43(2) together form the institutional entry point for language requirements. The instructions for use are an approved document, and the labelling requirements are determined by the Ministry of Health. When preparing these two types of documents, their format, language and content elements all depend on the specifications of the Ministry of Health. The GRZAN practical approach is to treat the language versions of the instructions and labels as part of the registration approval, confirming them with the Ministry of Health at submission rather than supplementing them after the certificate is issued.

Insight 3: Article 44(5) implies a language requirement for information disclosure. The provision requires registration and withdrawal information to be published by the supervisory authority in the relevant publications. The language of Tajik publications is naturally Tajik or Russian. The practical value of this clause is that companies can track the publications of the supervisory authority to obtain registration status and withdrawal information, and that tracking work requires Russian or Tajik language capability.

Insight 4: Russian carries the main communication function in practice, but this is not the same as a legal requirement. Russian is the language of interethnic communication in Tajikistan, and practical communication with government bodies and professional institutions relies heavily on it. The GRZAN experience is that Russian versions of registration materials are widely accepted in practice, but Tajik versions may be required at specific points, such as public-facing labels and instructions. The recommendation is to prepare materials on the basis of Russian as the primary language with Tajik added where needed, and to confirm this before submission.

Insight 5: The risk of language issues lies in the determination benchmark, not in translation quality alone. Read together with Article 33(2), under which technical testing examines the product against the intended use defined in the manufacturer’s documents, and Article 16(7), under which quality requirements follow the documents relied upon at registration, the conclusion is that once a translated document is accepted, it becomes the determination benchmark. The consequence of a translation error is therefore not a mere communication obstacle but the possibility that a technical specification becomes fixed in Tajikistan in an erroneous version. GRZAN recommends that translations be countersigned jointly by the technical, quality and regulatory functions.

4. Practical recommendations

  1. Request the currently valid language specification documents. Under Article 17(12) and Article 43(2), request the current registration procedural documents and labelling specifications from the Ministry of Health, confirm the specific language requirements, and retain the version information on record.
  2. Prepare materials with Russian as the primary language and Tajik where needed. GRZAN recommends preparing Russian versions of the registration materials and instructions, and assessing whether Tajik versions are required for labels and public-facing instructions according to the specifications.
  3. Have translations countersigned by the technical, quality and regulatory functions. Under Article 33(2) and Article 16(7), the translation becomes the benchmark for subsequent determinations. Establish a joint countersignature process focusing on technical parameters, units, warnings and contraindication wording.
  4. Confirm language versions at submission, not after the certificate is issued. Under Article 1(21), the instructions are an approval object. Confirm the language versions with the Ministry of Health during the submission stage to avoid re-approval after the certificate is granted.
  5. Build regulatory tracking capability in Russian or Tajik. Under Article 44(5), registration and withdrawal information is published in Tajik publications. Assign staff with the relevant language capability or commission a local agency for periodic searches.

5. Verification checklist

  • □ The currently valid registration procedural documents and labelling specifications have been obtained and language requirements confirmed (Article 17(12), Article 43(2))
  • □ Materials and instruction versions have been prepared with Russian as the primary language and Tajik where needed
  • □ Translations have completed the joint countersignature of the technical, quality and regulatory functions
  • □ Language versions have been confirmed with the Ministry of Health at the submission stage (Article 1(21))
  • □ Regulatory tracking capability in Russian or Tajik has been established (Article 44(5))
  • □ Accuracy of the translation of technical parameters, units, warnings and contraindications has been checked
  • □ Consistency of language versions between advertising texts and the instructions has been confirmed (Article 45(6), where advertising is involved)

Regulatory information verified as of October 29, 2026.

In the Central Asian market, GRZAN focuses its core capabilities on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a national track and a Union track coexist; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries, undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system compliant with ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail